TY - JOUR T1 - MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. A1 - O'Hagan,Derek T, PY - 2007/10/13/pubmed PY - 2007/12/6/medline PY - 2007/10/13/entrez SP - 699 EP - 710 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 6 IS - 5 N2 - In preclinical studies, MF59 adjuvant offered improved protection against influenza virus challenge and significantly reduced the viral load in the lungs of challenged mice. In humans, MF59 is a safe and potent vaccine adjuvant that has been licensed in more than 20 countries (Fluad [Novartis Vaccines and Diagnostics Inc., MA, USA]). The safety profile of an MF59-adjuvanted vaccine is well established through a large safety database. MF59 adjuvant has had a significant impact on the immunogenicity of influenza vaccines in the elderly and in adults who are chronically ill. MF59 has also been shown to have a significant impact on the immunogenicity of pandemic influenza vaccines. MF59 allows for broader cross-reactivity against viral strains not included in the vaccine. MF59 has been shown to be more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/17931151/MF59_is_a_safe_and_potent_vaccine_adjuvant_that_enhances_protection_against_influenza_virus_infection_ L2 - https://www.tandfonline.com/doi/full/10.1586/14760584.6.5.699 DB - PRIME DP - Unbound Medicine ER -